DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability
- PMID: 20821252
- DOI: 10.1007/s10555-010-9253-0
DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability
Abstract
Metastasis is a leading cause of mortality and morbidity in cancer. This process needs angiogenesis. The biology underlying cancer, metastasis, and angiogenesis has been investigated so as to determine the therapeutic targets. Invasive and metastatic cancer cells have undergone numerous genetic and epigenetic changes, manifested by cytoskeletal changes, loss of adhesion, and expression of proteolytic enzymes that degrade the basement membrane. Additionally, in endothelial cells, some epigenetic modifications occur during the formation of angiogenesis. Researchers have used some methylation inhibitors, histone deacetylase inhibitors, or methylating agents (such as S-adenosylmethionine, SAM) against cancer and angiogenesis. Although they are effective to beat these diseases, each one results in differentiation or changes in genome structure. We review epigenetically modified genes related with angiogenesis and metastasis in cancer and endothelial cells, and suggest a new proposal. This hypothesis has discussed the importance of the usage of DNA methylation inhibitors together with SAM to prevent tumor progression and genome instability or changes resulting in additional diseases.
Similar articles
-
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066. J Cell Physiol. 2007. PMID: 17458893 Review.
-
Targeting DNA methylation in cancer.Bull Cancer. 2006 Sep;93(9):961-72. Bull Cancer. 2006. PMID: 16980240
-
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.IDrugs. 2007 Aug;10(8):557-61. IDrugs. 2007. PMID: 17665331 Review.
-
Inhibition of angiogenesis by S-adenosylmethionine.Biochem Biophys Res Commun. 2011 Apr 29;408(1):145-8. doi: 10.1016/j.bbrc.2011.03.138. Epub 2011 Apr 2. Biochem Biophys Res Commun. 2011. PMID: 21463611
-
Epigenetic mechanisms in glioblastoma multiforme.Semin Cancer Biol. 2009 Jun;19(3):188-97. doi: 10.1016/j.semcancer.2009.02.005. Epub 2009 Feb 20. Semin Cancer Biol. 2009. PMID: 19429483 Review.
Cited by
-
Loss of mdig expression enhances DNA and histone methylation and metastasis of aggressive breast cancer.Signal Transduct Target Ther. 2018 Sep 21;3:25. doi: 10.1038/s41392-018-0027-4. eCollection 2018. Signal Transduct Target Ther. 2018. PMID: 30254753 Free PMC article.
-
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications.Oncogene. 2020 Sep;39(39):6139-6156. doi: 10.1038/s41388-020-01432-7. Epub 2020 Aug 24. Oncogene. 2020. PMID: 32839493 Free PMC article. Review.
-
The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting.Cancers (Basel). 2018 Aug 10;10(8):268. doi: 10.3390/cancers10080268. Cancers (Basel). 2018. PMID: 30103412 Free PMC article. Review.
-
Modification Patterns of DNA Methylation-Related lncRNAs Regulating Genomic Instability for Improving the Clinical Outcomes and Tumour Microenvironment Characterisation of Lower-Grade Gliomas.Front Mol Biosci. 2022 Mar 10;9:844973. doi: 10.3389/fmolb.2022.844973. eCollection 2022. Front Mol Biosci. 2022. PMID: 35359593 Free PMC article.
-
Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b.Mol Biol Rep. 2020 Mar;47(3):1649-1658. doi: 10.1007/s11033-020-05252-6. Epub 2020 Jan 10. Mol Biol Rep. 2020. PMID: 31925643
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
